Developing a New Rare Disease Diagnostic: From Fueling Clinical Trials to Building a Market

Many of the 7,000 rare diseases worldwide lack a standardized diagnostic test. Without a reliable diagnostic test, most patients are left unable to get a proper diagnosis, access potential treatment options or manage the disease.

This session will provide a case study of a collaboration between a pharma company and a national diagnostics lab that led to the commercialization of a quantitative diagnostic test for HDV. Panelists will share insights into how pharma companies can work with patient advocacy groups to educate physicians and patients about new diagnostics and the need for testing.